Introduction
The Industrial Property Act, 2014 (herein referred to as the Act), enacted as Chapter 224 of the Laws of Uganda, serves as a cornerstone for regulating intellectual property rights, particularly patents, in the country. Section 12(b) of the Act explicitly excludes from patentability inventions that are contrary to public order, morality, public health and safety, public policy, principles of humanity, and environmental conservation. This provision aligns Uganda’s patent regime with international standards, such as those under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), while incorporating local contextual considerations. The right to health, though not expressly enshrined as a justiciable right in Uganda’s 1995 Constitution, is implied through National Objectives and Directive Principles of State Policy (Objective XX) and international commitments like the International Covenant on Economic, Social and Cultural Rights (ICESCR), which Uganda ratified in 1987. This essay examines how the exemption in Section 12(b) impacts the right to health in Uganda, drawing on case law to illustrate its protective role, potential limitations, and broader implications. Through a structured analysis, it argues that while the exemption generally safeguards public health by preventing the monopolisation of harmful inventions, it may occasionally hinder access to innovative health solutions in a resource-constrained setting. The discussion will proceed by outlining the Act and the right to health, analysing the exemption’s rationale, reviewing relevant case law, and evaluating its impacts, ultimately highlighting the need for balanced interpretation.
Overview of the Industrial Property Act 2014
The Industrial Property Act, 2014, replaced the outdated Patents Act of 1993 to modernise Uganda’s intellectual property framework in line with global trade obligations. Administered by the Uganda Registration Services Bureau, the Act promotes innovation by granting inventors exclusive rights for a limited period, typically 20 years, provided the invention is novel, inventive, and industrially applicable (Section 9). However, Section 12 introduces exclusions to prevent the patent system from endorsing socially detrimental creations. Specifically, Section 12(b) states that patents shall not be granted for “inventions the prevention within Uganda of the commercial exploitation of which is necessary to protect public order or morality, including to protect human, animal or plant life or health or to avoid serious prejudice to the environment” (Industrial Property Act, 2014). This phrasing echoes Article 27(2) of the TRIPS Agreement, allowing member states flexibility to exclude inventions that threaten public welfare.
In the Ugandan context, this exemption reflects a cautious approach to intellectual property, prioritising societal values over unbridled innovation. For instance, it could bar patents for technologies promoting unsafe medical practices or environmentally harmful pharmaceuticals. While the Act’s implementation has been gradual, with limited patent registrations annually (often under 100, as reported by the World Intellectual Property Organization), Section 12(b) underscores Uganda’s commitment to integrating ethical considerations into its legal system (WIPO, 2022). This framework is particularly relevant to health, where patents can influence drug affordability and access, especially in a country facing high burdens of diseases like HIV/AIDS and malaria.
The Right to Health in Uganda
The right to health in Uganda is not a standalone constitutional entitlement but is embedded within broader socio-economic objectives. The 1995 Constitution’s Objective XX mandates the state to “take practical measures to ensure the provision of basic medical services to the population,” implying a duty to promote health access (Constitution of Uganda, 1995). This is reinforced by Uganda’s ratification of the ICESCR, where Article 12 recognises “the right of everyone to the enjoyment of the highest attainable standard of physical and mental health” (UN, 1966). Domestically, the right has been judicially interpreted in cases emphasising state obligations, such as providing essential medicines.
However, enforcement remains challenging due to resource limitations and the non-justiciable nature of directive principles. The Ugandan judiciary has occasionally invoked these principles to hold the government accountable, as seen in health-related litigation. Generally, the right encompasses access to healthcare, preventive measures, and protection from health hazards, aligning with global standards from the World Health Organization (WHO). In patent law, this right intersects with intellectual property by influencing how exclusions like Section 12(b) can either facilitate or obstruct health innovations.
The Exemption under Section 12(b) and Its Rationale
Section 12(b) serves as a moral and ethical gatekeeper in Uganda’s patent system, preventing the grant of monopolies to inventions deemed harmful. The rationale is rooted in public policy, aiming to discourage innovations that could undermine societal well-being. For health specifically, the exemption targets inventions contrary to “public health and safety,” such as those involving hazardous substances or unethical medical procedures. Arguably, this promotes the right to health by ensuring that patents do not incentivise or protect detrimental technologies, thereby fostering a safer innovation environment.
Critically, however, the provision’s broad language invites subjective interpretation. What constitutes “contrary to morality” or “public health” may vary, potentially leading to over-exclusion of borderline inventions, like certain biotechnologies. In practice, this could limit patent protection for health-related inventions perceived as risky, affecting research incentives. Furthermore, in a developing country like Uganda, where health infrastructure is fragile, the exemption might indirectly support generic drug production by denying patents to exploitative inventions, thus enhancing affordability (Ncube, 2016). Yet, without clear guidelines, it risks inconsistent application, as evidenced in similar jurisdictions.
Case Law Analysis
Case law provides insight into how exemptions akin to Section 12(b) impact health rights, though Ugandan-specific precedents are limited due to the Act’s recency and low litigation volume. Domestically, the case of Centre for Health, Human Rights and Development (CEHURD) v Attorney General (Constitutional Petition No. 16 of 2011) is instructive, albeit not directly on patents. Here, the Constitutional Court affirmed the state’s duty to provide maternal health services, interpreting Objective XX as imposing obligations to protect health (CEHURD v AG, 2012). Extending this, the exemption in Section 12(b) could be seen as a mechanism to prevent patents that exacerbate health inequalities, such as those for unaffordable drugs conflicting with public policy.
Internationally, cases from compatible jurisdictions illuminate potential applications. In Harvard College v Commissioner of Patents (2002 SCC 76), the Canadian Supreme Court denied a patent for a genetically modified mouse (oncomouse) on grounds similar to morality exclusions, arguing it commodified life forms contrary to public order. This resonates with Uganda’s Section 12(b), particularly for health biotechnologies, where patent denials could protect against ethical breaches in medical research, thereby upholding the right to health by prioritising human dignity (Harvard College, 2002).
Another relevant case is Novartis AG v Union of India (2013) from India, where the Supreme Court rejected a patent for the cancer drug Glivec under Section 3(d) of India’s Patents Act, which excludes incremental innovations unless they enhance efficacy. The court emphasised public health access, noting that overly broad patents hinder affordable generics (Novartis AG, 2013). Although not Ugandan, this mirrors Section 12(b)’s health safeguard, suggesting that Uganda could use the exemption to deny patents for inventions that prioritise profit over public health, positively impacting access to treatments for diseases prevalent in Uganda, like tuberculosis.
These cases demonstrate a logical argument for the exemption’s role in balancing innovation with health rights, though they also highlight limitations, such as potential deterrence of foreign investment in health technologies.
Impacts on the Right to Health
The exemption under Section 12(b) primarily positively impacts the right to health by deterring harmful inventions and promoting equitable access. By excluding patents for health-damaging technologies, it prevents monopolies that could inflate costs or encourage unsafe practices, aligning with WHO guidelines on intellectual property and public health (WHO, 2015). For example, in Uganda’s context of high HIV prevalence, denying patents for morally questionable drug formulations could facilitate generic production, reducing prices and enhancing accessibility.
However, there are drawbacks. The provision’s vagueness might lead to under-patenting of beneficial but controversial inventions, such as stem cell therapies, potentially stifling innovation in a country reliant on imported health technologies (Mgbeoji, 2006). Moreover, in resource-poor settings, this could exacerbate dependency on foreign aid, indirectly undermining the right to health. Critically, while the exemption protects against direct harms, it does not address broader issues like patent evergreening, which case law like Novartis critiques. Therefore, its overall impact is protective yet limited, requiring judicial clarity to maximise benefits.
Conclusion
In summary, Section 12(b) of Uganda’s Industrial Property Act, 2014, plays a vital role in safeguarding the right to health by excluding patents for inventions contrary to public health and morality, as illustrated through cases like CEHURD v AG and international precedents such as Harvard College and Novartis. This exemption fosters ethical innovation and access to affordable health solutions, though its broad scope risks hindering progressive developments. The implications underscore the need for interpretive guidelines to ensure it enhances, rather than obstructs, health rights in Uganda. Ultimately, balancing intellectual property with human rights remains essential for sustainable development.
References
- Constitution of the Republic of Uganda. (1995) Kampala: Government of Uganda.
- Harvard College v Commissioner of Patents. (2002) SCC 76. Supreme Court of Canada.
- Industrial Property Act. (2014) Act No. 3 of 2014. Uganda Legal Information Institute.
- Mgbeoji, I. (2006) Global biopiracy: Patents, plants, and indigenous knowledge. UBC Press.
- Ncube, C. B. (2016) Intellectual property policy, law and administration in Africa: Exploring continental and sub-regional co-operation. Routledge.
- Novartis AG v Union of India. (2013) Civil Appeal Nos. 2706-2716 of 2013. Supreme Court of India.
- United Nations. (1966) International Covenant on Economic, Social and Cultural Rights. Adopted by General Assembly resolution 2200A (XXI).
- World Health Organization. (2015) WHO guideline on country pharmaceutical pricing policies. WHO Press.
- World Intellectual Property Organization. (2022) World intellectual property indicators 2022. WIPO.
